Book contents
- OptogeneticsFrom Neuronal Function to Mapping and Disease Biology
- Optogenetics
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Part I Optogenetics in Model Organisms
- Part II Opsin Biology, Tools, and Technology Platform
- Part III Optogenetics in Neurobiology, Brain Circuits, and Plasticity
- Part IV Optogenetics in Learning, Neuropsychiatric Diseases, and Behavior
- Part V Optogenetics in Vision Restoration and Memory
- Part VI Optogenetics in Sleep, Prosthetics, and Epigenetics of Neurodegenerative Diseases
- 28 Optogenetic Dissection of Sleep–Wake Control: Evidence for a Thalamic Control of Sleep Architecture
- 29 Optogenetics and Auditory Implants
- 30 Optogenetic Stimulation for Cochlear Prosthetics
- 31 The Role of Amino Acids in Neurodegenerative and Addictive Diseases
- 32 Optogenetics in Deep Brain Stimulation: Ethical Considerations
- Index
- Plate Section (PDF Only)
- References
32 - Optogenetics in Deep Brain Stimulation: Ethical Considerations
from Part VI - Optogenetics in Sleep, Prosthetics, and Epigenetics of Neurodegenerative Diseases
Published online by Cambridge University Press: 28 April 2017
Edited by
Book contents
- OptogeneticsFrom Neuronal Function to Mapping and Disease Biology
- Optogenetics
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Part I Optogenetics in Model Organisms
- Part II Opsin Biology, Tools, and Technology Platform
- Part III Optogenetics in Neurobiology, Brain Circuits, and Plasticity
- Part IV Optogenetics in Learning, Neuropsychiatric Diseases, and Behavior
- Part V Optogenetics in Vision Restoration and Memory
- Part VI Optogenetics in Sleep, Prosthetics, and Epigenetics of Neurodegenerative Diseases
- 28 Optogenetic Dissection of Sleep–Wake Control: Evidence for a Thalamic Control of Sleep Architecture
- 29 Optogenetics and Auditory Implants
- 30 Optogenetic Stimulation for Cochlear Prosthetics
- 31 The Role of Amino Acids in Neurodegenerative and Addictive Diseases
- 32 Optogenetics in Deep Brain Stimulation: Ethical Considerations
- Index
- Plate Section (PDF Only)
- References
- Type
- Chapter
- Information
- OptogeneticsFrom Neuronal Function to Mapping and Disease Biology, pp. 463 - 469Publisher: Cambridge University PressPrint publication year: 2017
References
Adamantidis, A., Arber, S., Bains, J. S., Bamberg, E., Bonci, A., Buzsáki, G., et al. 2015. Optogenetics: 10 years after ChR2 in neurons – views from the community. Nature Neuroscience, 18(9): 1202–1212.CrossRefGoogle ScholarPubMed
Brewer, C. D. & Nicolai, E., 2014. Reassessing the ethical importance of efficacy and autonomy in optogenetics trials. AJOB Neuroscience, 5(3): 16–18.CrossRefGoogle Scholar
Canli, T., 2015. Neurogenethics: an emerging discipline at the intersection of ethics, neuroscience, and genomics. Applied & Translational Genomics, 5: 18–22.CrossRefGoogle ScholarPubMed
Cavanaugh, J., Monosov, I. E., McAlonan, K., Berman, R., Smith, M. K., Cao, V., et al. 2012. Optogenetic inactivation modifies monkey visuomotor behavior. Neuron, 76(5): 901–907.CrossRefGoogle ScholarPubMed
Chen, B. T., Yau, H.-J., Hatch, C., Kusumoto-Yoshida, I, Cho, S. L., Hopf, W., et al. 2013. Rescuing cocaine-induced prefrontal cortex hypoactivity prevents compulsive cocaine seeking. Nature, 496: 359–364.CrossRefGoogle ScholarPubMed
Covington, H. E., Lobo, M. K., Maze, I., Vialou, V., Hyman, J. M., Zaman, S., et al. 2010. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. Journal of Neuroscience, 30(48): 16082–16090.CrossRefGoogle ScholarPubMed
Deisseroth, K., 2012. Optogenetics and psychiatry: applications, challenges, and opportunities. Biological Psychiatry, 71: 1030–1032.CrossRefGoogle ScholarPubMed
Diester, I., Kaufman, M. T., Mogri, M., Pashaie, R., Goo, W., Yizhar, O., et al. 2011. An optogenetic tool box designed for primates. Nature Neuroscience, 14(3): 387–397.CrossRefGoogle Scholar
Gilbert, F., Harris, A. R., & Kapsa, R. M. I. 2014. Controlling brain cells with light: ethical considerations for optogenetic clinical trials. AJOB Neuroscience 5(3): 3–11.CrossRefGoogle Scholar
Gradinaru, V. 2013. Optogenetics to benefit human health: opportunities and challenges. In: Hegemann, P. & Sigrist, S. (Eds.): Optogenetics. Berlin & Boston: De Gruyter: 127–131.CrossRefGoogle Scholar
Hess, P., 2014. The ethical dilemmas of experimental invasive brain technology. AJOB Neuroscience, 5(3): 18–20.CrossRefGoogle Scholar
Kravitz, A. V., Freeze, B. S., Parker, P. R., Kay, K., Thwin, M. T., Deisseroth, K., et al. 2010. Regulation of parkinsonian motor behaviours by optogenetic control of basalganglia circuitry. Nature, 466: 622–626.CrossRefGoogle Scholar
LaLumiere, R. T., 2011. A new technique for controlling the brain: optogenetics and its potential for the use in research and the clinic. Brain Stimulation, 4: 1–6.CrossRefGoogle ScholarPubMed
Lidz, C. W., Appelbaum, P. S., Grisso, T., & Renaud, M. 2004. Therapeutic misconception and the appreciation of risks in clinical trials. Social Science & Medicine, 58: 1689–1697.CrossRefGoogle ScholarPubMed
Liu, X., Ramirez, S., Pang, P. T., Puryear, C. B., Govindarajan, A., Deisseroth, K., et al. 2012. Optogenetic stimulation of a hippocampal engram activates fear memory recall. Nature, 484: 381–385.CrossRefGoogle ScholarPubMed
Maslen, H. & Savulescu, J., 2014. First Phase 1 optogenetics trials should be conducted in people who are dying. AJOB Neuroscience, 5(3): 16–18.CrossRefGoogle Scholar
Müller, S. & Walter, H., 2014. Neither speculative nor narrow-minded ethics is needed for optogenetics-based DBS in psychiatry and neurology. AJOB Neuroscience, 5(3): 12–20.CrossRefGoogle Scholar
Okano, H., Miyawaki, A., & Kasai, K., 2015. Brain/MINDS: brain-mapping project in Japan. Phil. Trans. R. Soc. B, 370: 20140310.CrossRefGoogle ScholarPubMed
Pama, E. A. C., Colzato, L. S., & Hommel, B., 2013. Optogenetics as a neuromodulation tool in cognitive neuroscience. Frontiers in Psychology, 4: 610.CrossRefGoogle ScholarPubMed
Pastrana, E., 2011. Nature methods primer: optogenetics: controlling cell function with light. Nature Methods, 8(1): 24–25.CrossRefGoogle Scholar
Schleiermacher, S., 2013. History in the making: the ethics of optogenetics. In: Hegemann, P. & Sigrist, S. (Eds.): Optogenetics. Berlin & Boston: De Gruyter: 199–200.Google Scholar
Sturm, V., 2013. Potential of optogenetics in deep brain stimulation. In: Hegemann, P. & Sigrist, S. (Eds.): Optogenetics. Berlin & Boston: De Gruyter: 157–160.CrossRefGoogle Scholar
Yoon, H. H., Min, J., Hwang, E., Lee, C. J., Suh, J.-K., Hwang, O., et al. 2016. Optogenetic inhibition of the subthalamic nucleus reduces levodopa-induced dyskinesias in a rat model of Parkinson’s disease. Stereotactic and Functional Neurosurgery, 94: 41–53.CrossRefGoogle Scholar
Walter, H. & Müller, S., 2013. Optogenetics as a new therapeutic tool in medicine? A view from the principles of biomedical ethics. In: Hegemann, P. & Sigrist, S. (Eds.): Optogenetics. Berlin & Boston: De Gruyter: 201–211.CrossRefGoogle Scholar
Zhang, F., Gradinaru, V., Adamantidis, A. R., Durand, R., Airan, R. D., de Lecea, L., et al. 2010. Optogenetic interrogation of neural circuits: technology for probing mammalian brain structures. Nature Protocols, 5: 439–456.CrossRefGoogle Scholar